- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT00778102
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
2016. november 1. frissítette: Hoffmann-La Roche
A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus Bevacizumab (OLIVIA)
This 2 arm study will compare the resection rate of liver metastases and safety of surgery in patients with metastatic colorectal cancer and primarily unresectable liver metastases receiving treatment with Avastin in combination with 5-FU, leucovorin and oxaliplatin with irinotecan (FOLFOXIRI) or without irinotecan (mFOLFOX-6) as first line treatment.
Patients will be randomized to receive Avastin (5mg/kg iv every 2 weeks) in combination with each of these two standard neoadjuvant chemotherapy regimens.
The anticipated time on study treatment is until surgery, disease progression, unacceptable toxicity or patient refusal, and the target sample size is <100 individuals.
A tanulmány áttekintése
Állapot
Befejezve
Körülmények
Tanulmány típusa
Beavatkozó
Beiratkozás (Tényleges)
80
Fázis
- 2. fázis
Kapcsolatok és helyek
Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.
Tanulmányi helyek
-
-
-
Wien, Ausztria, 1090
-
-
-
-
-
London, Egyesült Királyság, WC1E 6DD
-
Manchester, Egyesült Királyság, M20 4QL
-
Sutton, Egyesült Királyság, SM2 5PT
-
Wirral, Egyesült Királyság, CH63 4JY
-
-
-
-
-
Bordeaux, Franciaország, 33075
-
Creteil, Franciaország, 94010
-
Le Mans, Franciaország, 72037
-
Lille, Franciaország, 59037
-
Lyon, Franciaország, 69373
-
Montpellier, Franciaország, 34298
-
Villejuif, Franciaország, 94804
-
-
-
-
-
Girona, Spanyolország, 17007
-
Madrid, Spanyolország, 28046
-
Madrid, Spanyolország, 28007
-
Valencia, Spanyolország, 46026
-
-
Guipuzcoa
-
San Sebastian, Guipuzcoa, Spanyolország, 20080
-
-
Islas Baleares
-
Palma de Mallorca, Islas Baleares, Spanyolország, 07198
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Spanyolország, 15706
-
-
Részvételi kritériumok
A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.
Jogosultsági kritériumok
Tanulmányozható életkorok
18 év és régebbi (Felnőtt, Idősebb felnőtt)
Egészséges önkénteseket fogad
Nem
Tanulmányozható nemek
Összes
Leírás
Inclusion Criteria:
- adult patients, >=18 years of age;
- unresectable liver metastasis secondary to cancer of colon or rectum;
- scheduled for standard first line chemotherapy;
- ECOG performance score of 0 or 1;
- condition feasible for major abdominal surgery after first line treatment.
Exclusion Criteria:
- diagnosis of metastatic disease >3 months prior to study entry;
- evidence of extrahepatic disease, diffuse peritoneal carcinosis or involvement of celiac lymph nodes;
- prior systemic or local treatment of metastatic disease;
- prior (neo)adjuvant chemotherapy/radiotherapy completed within 6 months prior to study entry;
- history or evidence of CNS disease unrelated to cancer.
Tanulási terv
Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: 1
|
85 mg/m2 2 órás iv. infúzió, 2 hetente 1. napon
200 mg/m2 2 órás iv. infúzió, 2 hetente 1. napon
2400mg/m2 46 órás folyamatos iv infúzió, 2 hetente 1. nap
Bolus 400mg/m2, day 1 every 2 weeks
3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
400mg/m2 2-hour iv infusion, day 1 every 2 weeks
5mg/kg iv day 1 every 2 weeks
|
Aktív összehasonlító: 2
|
85 mg/m2 2 órás iv. infúzió, 2 hetente 1. napon
200 mg/m2 2 órás iv. infúzió, 2 hetente 1. napon
2400mg/m2 46 órás folyamatos iv infúzió, 2 hetente 1. nap
Bolus 400mg/m2, day 1 every 2 weeks
3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
400mg/m2 2-hour iv infusion, day 1 every 2 weeks
5mg/kg iv day 1 every 2 weeks
165mg/m2 1-hour iv infusion, day 1 every 2 weeks
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor
Időkeret: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
|
Following resective surgery, participants were evaluated for complete resection (R0) or the presence of microscopic (R1) or macroscopic (R2) residual tumor.
The percentage of participants within each residual tumor classification was calculated as [number of participants with R0, R1, and/or R2 divided by the total number of participants] multiplied by 100.
Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method.
|
Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Time to Resection
Időkeret: Up to 5 years (at Screening; prior to each cycle, and within 7 days prior to surgery; and at time of surgery)
|
Time to resection was defined as the time from randomization to the date of first resective surgery.
For participants who did not undergo resective surgery, time to resection was censored at Day 1.
Time to resection was estimated by Kaplan-Meier analysis.
|
Up to 5 years (at Screening; prior to each cycle, and within 7 days prior to surgery; and at time of surgery)
|
Percentage of Participants With Histopathological Response
Időkeret: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
|
At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability.
Histopathological response classification was based upon the percentage of viable tumor cells, where 'Complete response' was considered for those with 0 percent (%) viable tumor cells, 'Major response' for those with 1% to 49% viable tumor cells, 'Minor response' for 50% to 99% viable tumor cells, and 'No response' for 100% viable tumor cells.
The response could not be determined in some cases and was documented as 'Unknown.'
The percentage of participants within each response category was calculated as [number of participants with a given response divided by the number of participants who completed the assessment] multiplied by 100.
|
Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
|
Percentage of Participants With Complete or Major Histopathological Response
Időkeret: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
|
At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability.
Histopathological response classification was based upon the percentage of viable tumor cells, as described previously.
The collective percentage of participants assessed as having a complete or major response was calculated as [number of participants with complete or major response divided by the number of participants who completed the assessment] multiplied by 100.
Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method.
|
Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
|
Percentage of Participants Experiencing Relapse Following Curative Resection
Időkeret: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Among participants with curative resection (complete resection [R0] or microscopic residual tumor [R1]), relapse was defined as the first new occurrence of cancer or death.
The percentage of participants who experienced relapse was calculated as [number of participants with a relapse event divided by the number of participants initially classified as R0 or R1 following resective surgery] multiplied by 100.
|
Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Relapse-Free Survival (RFS)
Időkeret: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
RFS was defined as the time from curative resection (complete resection [R0] or microscopic residual tumor [R1]) to the date of first diagnosis of relapse.
For participants with curative resection and without relapse, RFS was censored at the last known relapse-free assessment.
RFS was estimated by Kaplan-Meier analysis.
|
Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Percentage of Participants Experiencing Death or Disease Progression
Időkeret: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
|
PD was defined, using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions.
The percentage of participants experiencing PD or death was calculated as [number of participants with event divided by the number of participants analyzed] multiplied by 100.
|
Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
|
Progression-Free Survival (PFS)
Időkeret: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
|
PFS was defined, using RECIST version 1.0, as the time from randomization to the date of first documented PD or death from any cause.
PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions.
For participants without documented PD or death, PFS was censored at the time of last tumor assessment.
PFS was estimated by Kaplan-Meier analysis.
|
Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
|
Percentage of Participants Who Died
Időkeret: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
|
Overall Survival (OS)
Időkeret: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
OS was defined as the time from randomization to death from any cause.
For participants without an event of death, OS was censored at the last-known alive date.
OS was estimated by Kaplan-Meier analysis.
|
Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0
Időkeret: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
|
Using RECIST version 1.0, participants were considered to have achieved CR upon the disappearance of all target and non-target lesions.
Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter.
Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met.
The collective percentage of participants with confirmed best overall response of CR or PR was calculated as [number of participants meeting RECIST criteria for CR or PR divided by the number of participants analyzed] multiplied by 100.
Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method.
|
Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
|
Time to Response
Időkeret: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
|
Time to response according to RECIST version 1.0 was defined as the time from randomization to the date of first documented CR or PR.
Participants were considered to have achieved CR upon the disappearance of all target and non-target lesions.
Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter.
Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met.
For participants who did not complete a confirmatory tumor assessment, time to response was censored at the date of last tumor assessment, or if unavailable, at the date of first dose.
Time to response was estimated by Kaplan-Meier analysis.
|
Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
|
Percentage of Participants With Complications Related to First Resective Surgery
Időkeret: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Complications related to the first resective surgery were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, and classified according to severity.
The NCI-CTCAE severity classification criteria are as follows: Grade 5 equals (=) resulting in death; Grade 4 = life-threatening; Grade 3 = severe; Grade 2 = moderate; and Grade 1 = mild.
The percentage of participants experiencing a given adverse event (AE) by severity grade was calculated as [number of participants with an AE divided by the number of participants who underwent first resective surgery] multiplied by 100.
|
Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Percentage of Participants With Complications Related to Second Resective Surgery
Időkeret: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Complications related to the second resective surgery were evaluated using the NCI-CTCAE version 3.0, and classified according to severity.
The NCI-CTCAE severity classification criteria are as follows: Grade 5 = resulting in death; Grade 4 = life-threatening; Grade 3 = severe; Grade 2 = moderate; and Grade 1 = mild.
The percentage of participants experiencing a given AE by severity grade was calculated as [number of participants with an AE divided by the number of participants who underwent second resective surgery] multiplied by 100.
|
Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
|
Együttműködők és nyomozók
Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.
Szponzor
Publikációk és hasznos linkek
A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.
Általános kiadványok
- Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225. Online ahead of print.
- Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015 Apr;26(4):702-708. doi: 10.1093/annonc/mdu580. Epub 2014 Dec 23.
Tanulmányi rekorddátumok
Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.
Tanulmány főbb dátumok
Tanulmány kezdete
2008. október 1.
Elsődleges befejezés (Tényleges)
2013. október 1.
A tanulmány befejezése (Tényleges)
2013. október 1.
Tanulmányi regisztráció dátumai
Először benyújtva
2008. október 22.
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
2008. október 22.
Első közzététel (Becslés)
2008. október 23.
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Becslés)
2016. november 2.
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
2016. november 1.
Utolsó ellenőrzés
2016. november 1.
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Emésztőrendszeri betegségek
- Neoplazmák
- Neoplazmák webhelyenként
- Gasztrointesztinális neoplazmák
- Emésztőrendszeri neoplazmák
- Emésztőrendszeri betegségek
- Vastagbélbetegségek
- Bélbetegségek
- Bél neoplazmák
- Rektális betegségek
- Kolorektális neoplazmák
- A gyógyszerek élettani hatásai
- A farmakológiai hatás molekuláris mechanizmusai
- Enzim gátlók
- Antimetabolitok, daganatellenes
- Antimetabolitok
- Antineoplasztikus szerek
- Immunszuppresszív szerek
- Immunológiai tényezők
- Védőszerek
- Topoizomeráz gátlók
- Immunológiai daganatellenes szerek
- Angiogenezis gátlók
- Angiogenezist moduláló szerek
- Növekedést elősegítő anyagok
- Növekedésgátlók
- Mikrotápanyagok
- Vitaminok
- Topoizomeráz I gátlók
- Ellenszerek
- B-vitamin komplex
- Fluorouracil
- Oxaliplatin
- Bevacizumab
- Leucovorin
- Irinotekán
- Levoleukovorin
Egyéb vizsgálati azonosító számok
- MO18725
- 2007-007863-26
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Colorectalis rák
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)ToborzásAnatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Korai stádiumú emlőkarcinóma | Anatómiai Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Egyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Fred Hutchinson Cancer CenterMég nincs toborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institute on Aging (NIA)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Mayo ClinicNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)BefejezveVékonybél adenokarcinóma | III. stádiumú vékonybél-adenokarcinóma AJCC v8 | IIIA stádiumú vékonybél adenokarcinóma AJCC v8 | IIIB stádiumú vékonybél adenokarcinóma AJCC v8 | IV. stádiumú vékonybél adenokarcinóma AJCC v8 | Vater adenokarcinóma ampulla | Stage III Ampull of Vater Cancer AJCC v8 | Stage... és egyéb feltételekEgyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktív, nem toborzóStage II Breast Cancer AJCC v6 és v7 | Stage IIA Breast Cancer AJCC v6 és v7 | IIB stádiumú mellrák AJCC v6 és v7 | Stage III Breast Cancer AJCC v7 | IIIA stádiumú mellrák AJCC v7 | IIIB stádiumú mellrák AJCC v7 | IIIC stádiumú mellrák AJCC v7Egyesült Államok
-
Mayo ClinicNational Cancer Institute (NCI)BefejezveAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Anatómiai Stage 0 Breast Cancer AJCC v8Egyesült Államok
-
University of Southern CaliforniaNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Invazív emlőkarcinómaEgyesült Államok